BioCentury
ARTICLE | Product Development

Loxo to take on Imbruvica after reversible Btk inhibitor shines at ASH

December 7, 2020 11:45 PM UTC

With evidence suggesting reversible Btk inhibitor LOXO-305 can step in where covalent inhibitors of the same target have fallen short, Lilly is on track to draw more value from its already fruitful acquisition of Loxo.

New data presented at the American Society of Hematology (ASH) virtual meeting position LOXO-305 as a potential new therapy for patients who have failed other treatments including first-generation Btk inhibitor Imbruvica ibrutinib, but it also raises the question of how it stacks up to Imbruvica and how big its potential market could be...

BCIQ Company Profiles

Eli Lilly and Co.

BCIQ Target Profiles

Bruton's tyrosine kinase (Btk)